NCT04851535View on ClinicalTrials.gov

Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

November 1, 2022

Study Completion Date

November 1, 2022

Conditions

Myelofibrosis

Interventions

DRUG

Jaktinib Hydrochloride Tablets

Jaktinib 100mg Bid

Trial Locations (1)

310003

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT04851535 - Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment. | Biotech Hunter | Biotech Hunter